Bladder Cancer News and Research RSS Feed - Bladder Cancer News and Research

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis.
BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015. [More]
MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. [More]
Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics Inc. announced today that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration. This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing. [More]
Telesta closes US$28.6 million in private placement financing

Telesta closes US$28.6 million in private placement financing

Telesta Therapeutics Inc. announced today that it has closed a private placement financing of US$28.6 million. This transaction was led by several prominent U.S. healthcare investors, including Consonance Capital Investors, Boxer Capital of Tavistock Life Sciences and Omega Funds. In addition, certain members of the senior management team and board of directors of Telesta participated in the transaction. [More]
Researchers develop new way to personalize treatments for bladder cancer

Researchers develop new way to personalize treatments for bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took bladder tumors from individual patients, identified actionable mutations and grafted the tumors into mice. [More]
Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. [More]
WI Harper Group announces investment in Cold Genesys

WI Harper Group announces investment in Cold Genesys

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc, a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer. [More]
Certain genes exposed to harsh environmental factors can increase diabetes risk

Certain genes exposed to harsh environmental factors can increase diabetes risk

Arsenic, which can be present in ground water, modifies an enzyme that alters the secretion of insulin in the pancreas. Physicians, usually, show type II diabetes as a consequence of an exaggerated food intake and lack of exercise; however, there are about 50 genes that cause changes in the DNA, known as polymorphisms, that when combined with harsh environmental factors are at increased risk of developing the disease, mentioned PhD Marta Ostrosky Wegman, director of the Institute for Biomedical Research the National University of Mexico (UNAM). [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up. [More]
Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA. [More]
Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders. [More]
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. [More]
E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer. [More]
The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition. [More]
Nanoplatform technology that detects early stages of cancer receives U.S. patent

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear. [More]
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. [More]
New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers. [More]
Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC). [More]
Advertisement
Advertisement